Sunitinib as First Line Therapy in Patients with Advanced Pancreatic Neuroendocrine Tumors: Experience of a Single Algerian Center

#1750

Introduction: Sunitinib is indicated in the treatment of patients with advanced progressive pancreatic neuroendocrine tumors (pNETs).Its experience as first line therapy is limited.

Aim(s): To evaluate efficacy and safety of sunitinib in a cohort of patients with advanced pNETs

Materials and methods: A retrospective review of patients with advanced pNETs receiving sunitinib 37,5 mg daily as first-line therapy between 2011 and 2016

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Djihed B, Alyda M, Mohammed O,

Keywords: pNETs,SUNITINIB ,first line.,